Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (73.88 KB, 1 trang )
The diagnosis is made clinically and confirmed by culture. The laboratory should be notified that diphtheria is
suspected, as the organism has specific culture requirements (cysteine-tellurite blood agar or modified Tinsdale
agar). Treatment involves administration of IV equine antitoxin (after tests for sensitivity to horse serum are
performed, as allergic reactions can be seen in up to 20% of patients) and antibiotics. Antibiotic treatment with
erythromycin (oral or parenteral) or penicillin G IM or IV for 14 days will stop toxin production and prevent
dissemination. Cutaneous lesions should be thoroughly washed with soap and water and treated with antimicrobial
treatment as discussed above. Household contacts and providers, irrespective of their immunization status, should
receive nasopharyngeal cultures and be offered PEP with either oral erythromycin or intramuscular penicillin G.
Persons receiving PEP also should be offered a booster dose of a diphtheria-containing vaccine. Droplet
precautions are recommended for all patients and carriers with pharyngeal diphtheria until nasopharyngeal cultures
collected 24 hours after completing antimicrobial treatment are negative.
Hantavirus
Hantaviruses are members of the Bunyaviridae family and are spread by infected rodents. Two different syndromes
have been reported: hemorrhagic fever with renal syndrome (HFRS) and Hantavirus cardiopulmonary syndrome.
The clinical features of HFRS include fever, hemorrhage, hypotension, and renal failure. The clinical features of
Hantavirus cardiopulmonary syndrome consist of a 2- to 8-day prodrome, and a febrile phase associated with
diffuse interstitial edema with respiratory compromise developing within 72 hours. Patients may develop chills,
headaches, vomiting, myalgia, and diarrhea. Symptoms typically seen with upper respiratory tract infections are
notably absent, except for cough. Laboratory findings include a neutrophilic leukocytosis with bandemia,
thrombocytopenia, and increased hemoglobin. Renal manifestations include proteinuria and hematuria. The
diagnosis is serologic. Treatment is supportive. Mortality rates approaching 40% have been reported for
Hantavirus cardiopulmonary syndrome, whereas death from HFRS is rare. Standard precautions are recommended;
it has not been associated with healthcare transmission or person-to-person infection.
Lymphadenopathy
The differential diagnosis for lymphadenopathy in the returned traveler is broad, and should include both
pathogens endemic to the region of travel as well as infectious agents with a global distribution. Most returned
travelers with infectious adenopathy will have viral etiologies, similar to the epidemiology in children who have
not traveled. However, there are some systemic diseases for which the initial manifestations may be
lymphadenopathy or lymphadenitis. These are summarized below. Filarial diseases, which cause lymphedema, are